EPHA2, a promising therapeutic target for hepatocellular carcinoma

被引：7
|
作者：
Wang, Hao
Qiu, Wei [1 ]
机构：
[1] Loyola Univ Chicago, Stritch Sch Med, Dept Surg, Maywood, IL 60153 USA
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2021年 / 8卷 / 03期
基金：
美国国家卫生研究院;
关键词：
EPHA2; HCC; AKT; STAT3; JAK1; INHIBITION; RECEPTOR; LIGAND;
D O I：
10.1080/23723556.2021.1910009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Identifying critical drivers of oncogenesis and tumor progression is essential for developing effective hepatocellular carcinoma (HCC) therapeutics. Our recent findings has demonstrated that targeting Ephrin Receptor A2 (EPHA2) suppresses HCC initiation and progression by dual inhibition of the Protein Kinase B (AKT) and Signal Transducer and Activator of Transcription 3 (STAT3) signaling.
引用
收藏
页数：3
相关论文
共 50 条
  • [41] EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma
    Qu-Jing Gai
    Zhen Fu
    Jiang He
    Min Mao
    Xiao-Xue Yao
    Yan Qin
    Xi Lan
    Lin Zhang
    Jing-Ya Miao
    Yan-Xia Wang
    Jiang Zhu
    Fei-Cheng Yang
    Hui-Min Lu
    Ze-Xuan Yan
    Fang-Lin Chen
    Yu Shi
    Yi-Fang Ping
    You-Hong Cui
    Xia Zhang
    Xindong Liu
    Xiao-Hong Yao
    Sheng-Qing Lv
    Xiu-Wu Bian
    Yan Wang
    Signal Transduction and Targeted Therapy, 7
  • [42] EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia
    Charmsaz, Sara
    Beckett, Kirrilee
    Smith, Fiona M.
    Bruedigam, Claudia
    Moore, Andrew S.
    Al-Ejeh, Fares
    Lane, Steven W.
    Boyd, Andrew W.
    PLOS ONE, 2015, 10 (06):
  • [43] Identification of G protein subunit alpha i2 as a promising therapeutic target of hepatocellular carcinoma
    Chen, Minbin
    Li, Zhifei
    Gu, Chengtao
    Zheng, Hao
    Chen, Yan
    Cheng, Long
    CELL DEATH & DISEASE, 2023, 14 (02)
  • [44] Identification of G protein subunit alpha i2 as a promising therapeutic target of hepatocellular carcinoma
    Minbin Chen
    Zhifei Li
    Chengtao Gu
    Hao Zheng
    Yan Chen
    Long Cheng
    Cell Death & Disease, 14
  • [45] Mathematical modeling of hepatocellular cancer progression via EphA2 and EGFR
    Nakamura, Naotoshi
    Muroi, Atsushi
    Asakura, Nobuhiko
    CANCER SCIENCE, 2022, 113 : 820 - 820
  • [46] EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma
    Lee, Jeong-Won
    Han, Hee Dong
    Shahzad, Mian M. K.
    Kim, Seung Wook
    Mangala, Lingegowda S.
    Nick, Alpa M.
    Lu, Chunhua
    Langley, Robert R.
    Schmandt, Rosemarie
    Kim, Hye-Sun
    Mao, Shenlan
    Gooya, John
    Fazenbaker, Christine
    Jackson, Dowdy
    Tice, David A.
    Landen, Charles N.
    Coleman, Robert L.
    Sood, Anil K.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (17): : 1193 - 1205
  • [47] EphA2 expression is associated with aggressive features in ovarian carcinoma
    Thaker, PH
    Deavers, M
    Celestino, J
    Thornton, A
    Fletcher, MS
    Landen, CN
    Kinch, MS
    Kiener, PA
    Sood, AK
    CLINICAL CANCER RESEARCH, 2004, 10 (15) : 5145 - 5150
  • [48] Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
    Rafaela Nasser Veiga
    Alexandre Luiz Korte de Azevedo
    Jaqueline Carvalho de Oliveira
    Daniela Fiori Gradia
    Journal of Molecular Medicine, 2024, 102 : 479 - 493
  • [49] Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
    Veiga, Rafaela Nasser
    de Azevedo, Alexandre Luiz Korte
    de Oliveira, Jaqueline Carvalho
    Gradia, Daniela Fiori
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2024, 102 (04): : 479 - 493
  • [50] IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma
    Xu, Junnv
    Lin, Haifeng
    Wu, Gang
    Zhu, Mingyue
    Li, Mengsen
    FRONTIERS IN ONCOLOGY, 2021, 11
12345